Ponatinib was approved by the US FDA on December 14, 2012, for patients with resistant or intolerant CML and Ph+ ALL, based on results of the PACE phase II trial reported days earlier at the annual ASH meeting.
•
At the 2010 annual meeting of the American Society of Hematology, ARIAD announced from a Phase I study of ponatinib in patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
American | American Civil War | American Broadcasting Company | American football | African American | American Idol | American Revolutionary War | American Revolution | Society of Jesus | Royal Society | American Association for the Advancement of Science | American Red Cross | National Geographic Society | American Library Association | American Museum of Natural History | American Express | American Academy of Arts and Sciences | American League | American Association | American Heart Association | American comic book | American Institute of Architects | American Airlines | American Hockey League | Spanish-American War | Pan American Games | American Cancer Society | Whitney Museum of American Art | American Ballet Theatre | American Legion |